B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL

P. Rodríguez-Otero, S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo, A.K. Nooka, S. Manier, N. Callander, L.J. Costa, R. Vij, N.J. Bahlis, P. Moreau, S.R. Solomon, M. Delforge, J. Berdeja, A. Truppel-Hartmann, Z. Yang, L. Favre-Kontula, F. Wu, J. Piasecki, M. Cook, S. Giralt

Open source

DOI: 10.1097/01.hs9.0000936124.56965.24
Published: 5
Container: HemaSphere
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/01.hs9.0000936124.56965.24,
  title = {B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL},
  author = {P. Rodríguez-Otero and S. Ailawadhi and B. Arnulf and K. Patel and M. Cavo and A.K. Nooka and S. Manier and N. Callander and L.J. Costa and R. Vij and N.J. Bahlis and P. Moreau and S.R. Solomon and M. Delforge and J. Berdeja and A. Truppel-Hartmann and Z. Yang and L. Favre-Kontula and F. Wu and J. Piasecki and M. Cook and S. Giralt},
  year = {2023},
  journal = {HemaSphere},
  doi = {10.1097/01.hs9.0000936124.56965.24},
  url = {https://doi.org/10.1097/01.hs9.0000936124.56965.24}
}

RIS

TY  - JOUR
TI  - B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL
AU  - P. Rodríguez-Otero
AU  - S. Ailawadhi
AU  - B. Arnulf
AU  - K. Patel
AU  - M. Cavo
AU  - A.K. Nooka
AU  - S. Manier
AU  - N. Callander
AU  - L.J. Costa
AU  - R. Vij
AU  - N.J. Bahlis
AU  - P. Moreau
AU  - S.R. Solomon
AU  - M. Delforge
AU  - J. Berdeja
AU  - A. Truppel-Hartmann
AU  - Z. Yang
AU  - L. Favre-Kontula
AU  - F. Wu
AU  - J. Piasecki
AU  - M. Cook
AU  - S. Giralt
PY  - 2023
JO  - HemaSphere
DO  - 10.1097/01.hs9.0000936124.56965.24
UR  - https://doi.org/10.1097/01.hs9.0000936124.56965.24
ER  -

APA

Rodríguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A., Manier, S., Callander, N., Costa, L., Vij, R., Bahlis, N., Moreau, P., Solomon, S., Delforge, M., Berdeja, J., Truppel-Hartmann, A., Yang, Z., Favre-Kontula, L., Wu, F., Piasecki, J., Cook, M., & Giralt, S. (2023). B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL. HemaSphere. https://doi.org/10.1097/01.hs9.0000936124.56965.24

Source records

doaj · retrieved 2026-09-26T11:49:05.027Z